Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum TRANSITION THERAPEUTICS INC. T.TTH

"Transition Therapeutics Inc is a product-focused biopharmaceutical company. The Company is engaged in developing therapeutics for disease indications with markets. Its technologies are focused on the treatment of Alzheimer's disease and diabetes."

TSX:TTH - Post Discussion

TRANSITION THERAPEUTICS INC. > 60 million cash and a promising lead drug
View:
Post by uptick144 on Jun 25, 2015 10:28am

60 million cash and a promising lead drug

This will bounce to five at a minimum!  "It has barely even traded any volume.  LOL..no brainer here
Comment by eunice12 on Jun 26, 2015 1:16pm
Canaccord target just $3.25. You guys are dreaming this will bounce back or that volume means anything. Traders don't work at TTH. ELND005 is toast per Canaccord report I read, and venturestockpicks doesn't even realize it was the lead product, although he mixes tenses in a play on words which curiously makes him technically correct that ELND005 is NO LONGER the lead drug.
Comment by Thuglife on Jun 26, 2015 9:28pm
This post has been removed in accordance with Community Policy
Comment by testfreak on Jun 26, 2015 11:03pm
eunice12 wrote: Canaccord target just $3.25. You guys are dreaming this will bounce back or that volume means anything. Traders don't work at TTH. ELND005 is toast per Canaccord report I read, and venturestockpicks doesn't even realize it was the lead product, although he mixes tenses in a play on words which curiously makes him technically correct that ELND005 is NO LONGER the lead drug.  ...more  
Comment by eunice12 on Jun 27, 2015 1:28am
Canaccord below assumes only 30% chance of success. Do you realize what happens to your money if the 70% occurs, and how much bigger 70 is than 30? Insane risk - consider how many slam dunk medical devices you can buy into nowadays with super low risk. "Assuming a probability of success of 30%, a royalty rate of 12% on peak revenues, and a discount rate of approximately 15%, we ...more  
Comment by testfreak on Jun 27, 2015 1:38am
nothing but nonesense. dont bother responding. i bet this well over $3.50 by mid end of july. stock is dirt cheap at this price. several projects going, and if u beleive what ever ANAL-ist well thats ur choice.
Comment by testfreak on Jun 27, 2015 1:39am
also noting several ANAL-ists have a buy rating on TTH and a hold. NO sells.... but that means nothing the ANAL-IST
Comment by eunice12 on Jun 27, 2015 1:55am
You are fixated on repetitive misspelling that word - do you have a point? They have an MSc, provide in depth analysis and spoke to clinicians in the field - which is a step up from a 2 sentence bb forecaster like you who makes it up as you go.  30% is not going to go away, no matter how many rabbits you pull out of that tinfoil hat.
Comment by testfreak on Jun 27, 2015 9:02am
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities